Subei, Adnan M.
Ontaneda, Daniel
Funding for this research was provided by:
National Institutes of Health (KL2 TR000440/TR/NCATS NIH HHS/United States)
Article History
First Online: 25 September 2015
Compliance with Ethical Standards
:
: A. Subei is supported by Clinician Care Physician Fellowship Award CF 00104N-1 from the National Multiple Sclerosis Society. Dr Ontaneda is supported by NIH CTSC KL2TR0000440 award. No funding was directly received by either author in the preparation of this manuscript.
: A Subei has received speaking fees from Genzyme. D. Ontaneda has received consulting fees from Acorda Therapeutics, Alkermes, Biogen Idec, Genzyme, Mallinckrodt, Novartis, and Teva.
Free to read: This content has been made available to all.